In your state, you are required to confirm you wish to access this information. Please enter 'QLD' or 'WA' in the field below to continue.

No thanks

China-Australia Free Trade Agreement: potential commercial implications

Mountain ranges

The China-Australia Free Trade Agreement (ChAFTA) was signed on the 17th June 2015, implementing a foundation in the next phase of inter-economic relationships between Australia and China. The potential for the ChAFTA to create opportunities for Australia is evident, with China accounting for Australia’s largest export market for goods and services and a nearly a third of total exports.

However, surrounding this growing economic relationship are questions around the potential implications of uncertainties about the standards of manufactured goods imported from China that do not meet Australia safety and quality regulations. What will be the implications of importing Chinese goods which may not pass Australia’s regulatory standards?

In its submissions to the Department of Foreign Affairs and Trade (DFAT) regarding the ChAFTA, the Australian Industry Group (AIG) has discussed the potential impacts that unsafe products from China that do not meet Australian safety and quality standards may have on Australian consumers and businesses. Furthermore, questions have been raised around whether the removal of tariffs under the ChAFTA could exacerbate these issues and how potential contract breaches and faulty Chinese products would be dealt with; with legal resolution channels becoming challenging.

More than 2000 recalls have been administered by the Australian Competition and Consumer Commission (ACCC) in the last 5 years, equating to 429 recalls per year on average.  In respect of faulty products, a recent review demonstrated that an average of 56% of goods were returned.

The ChAFTA will certainly have an impact on commercial Australia. It is without contention that there is mutual benefits for Australia and China from this agreement, with economists predicting that it will improve the efficiency of trade. Nonetheless, it can be expected that Australia will have to prepare for the consequences of circumventing strict safety and quality regulations in respect to a predicted escalation of Chinese imported goods.

 

Click for more information about product liability law.

Written by Shine Lawyers on . Last modified: September 21, 2017.

Join the discussion

Share this article:

There are 0 comments. Be the first!

Faulty High-tech braking systems: Subaru and Honda Recalls

The safety of cars with automatic braking systems have been called into question with car manufactures issuing worldwide recalls in response to faulty program software. Car manufactures Subaru and Honda have announced large recalls due to malfunctioning technology designed to prevent rear-end crashes and avoid hitting pedestrians, yet instead are putting the vehicles at risk […]

Read more

Breast implant suspended from Australian market

The Therapeutic Goods Association (TGA) has imposed a 6 month suspension on Cereform silicone gel-filled breast implants and associated sizers from the Australian Register of Therapeutic Goods. Since 2009, about 4800 of the implants were sold in Australia. The action taken by the TGA will now prevent the devices from being supplied to the Australian […]

Read more

Blood thinner Xarelto linked to potentially fatal bleeding

Clinical trials and post-market experience have linked widely used blood-thinning drug Xarelto and similar anticoagulants to incidences of major bleeding, some of which have been fatal. Xarelto works to reduce the tendency of blood to form clots and may be prescribed to prevent or treat blood clots in the brain, lungs, legs, or veins. Patients […]

Read more

Blood thinner to face action over fatal bleeding

A new blood thinning agent, marketed for having minimal side effects, may face litigation in the U.S. involving claims the medication has been linked to potentially fatal bleeding complications. Eliquis (Apixaban) is an anti-clotting agent used for persons with a heart irregularity known as atrial fibrillation to reduce risk of stroke. It is also used […]

Read more

Call Us Now

Our friendly consultants are available to talk Monday to Friday, 8:15am to 6:00pm AEST.

1800 618 851

Live Chat

Chat with Shine Lawyers through the livechat system without leaving your computer. No downloading, completely private and best of all - its easy to use.

Start a live chat now

Enquire Now

Enquire now